Outcomes after 6 months of continued treatment following hospitalisation*
| Pirfenidone (N=44) | Placebo (N=49) | Relative difference (%) | p Value† | |
|---|---|---|---|---|
| ≥10% decline in FVC or death | 4 (9.1%) | 16 (32.7%) | −72.2 | 0.010 |
| No further decline in FVC‡ | 15 (34.1%) | 12 (24.5%) | 39.2 | 0.364 |
| Death | 2 (4.5%) | 14 (28.6%) | −84.3 | 0.002 |
*All-cause hospitalisation between baseline and month 6; treatment outcomes assessed during the 6-month interval beginning with the first study visit following the date of hospitalisation.
†Fisher's exact test.
‡Either no decline or increase in FVC.